NK-104: A novel synthetic HMG-CoA reductase inhibitor

Expert Opinion on Investigational Drugs

Volumn 9, Issue 11, 2000, Pages 2653-2661

  Kajinami, K ^a   Mabuchi, H ^a   Saito, Y ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cytochrome P450; HMG CoA reductase inhibitor; LDL cholesterol; NK 104; Triglyceride

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA1 GLYCOPROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER; CHYLOMICRON; CYTOCHROME P450; CYTOCHROME P450 2C9; ERYTHROMYCIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; STEROL; TRIACYLGLYCEROL; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DOG; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; GUINEA PIG; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BRAIN LEVEL; NONHUMAN; RAT; TREATMENT PLANNING;

EID: 0033758172     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.11.2653     Document Type: Article

References (27)

1. The discovery and development of HMG-CoA reductase inhibitors
2. Drug treatment of lipid disorders
3. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
4. NK-104, a potent new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, enhances post-translational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells
5. NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells
6. Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver
7. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea-pigs
8. Hypolipidemic effect of NK-104 and other statins in guinea-pigs
9. Effect of NK-104 on postprandial triglyceride levels and lymph chylomicron in rats
10. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats
11. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): Interspecies variation in laboratory animals and humans
12. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human
13. Studies on the metabolic fate of itavastatin, a new inhibitor of HMG-CoA reductase: In vivo metabolism
14. NK-104: Efficacy and tolerance of a new synthetic HMG-CoA reductase inhibitor in hypercholesterolemic volunteers
15. NK-104 clinical evaluation committee. Clinical effect of NK-104 (nisvastatin) on hyperlipidemia: Double-blind comparative dose-findings study in three parallel groups
16. Japan itavastatin clinical study group: Efficacy and safety of NK-104 (itavastain) in hyperlipidemic subjects: A double-blind comparative study
17. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia
18. Efficacy and safety of a new HMG-CoA reductase inhibitor, NK-104, in patients with hypertriglyceridemia; randomized double-blind, cross-over placebo-controlled study
19. Effect of itavastatin on lipid metabolism in NIDDM patients with hyperlipidemia
20. Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia
21. Long-term effects of NK-104 (itavastatin), a new HMG-CoA reductase inhibitor, in patients with heterozygous familial hypercholesterolemia
22. Pharmacodynamics and pharmacokinetics of HMG-CoA reductase inhibitors
23. NK-104 (nisvastatin) suppresses foam cell formation induced by denatured low density lipoprotein in J774 macrophages
24. Itavastatin inhibits modified LDL-induced foam cell formation and scavenger pathway, mediated with Rab, Rho and Rac small G-protein, in RAW264.7 macrophages
25. Lipid-lowering and anti-atherosclerotic effect of NK-104 (nisvastatin), a new synthetic HMG-CoA reductase inhibitor, in WHHL rabbits
26. NK-104, a newly developed HMG-CoA reductase inhibitor, suppressed neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery